K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification

American Journal of Kidney Diseases

Volumn 39, Issue 2 SUPPL. 1, 2002, Pages

  Levey, Andrew S ^a   Coresh, Josef ^a   Bolton, Kline ^a   Culleton, Bruce ^a   Harvey, Kathy Schiro ^a   Ikizler, T Alp ^a   Johnson, Cynda Ann ^a   Kausz, Annamaria ^a   Kimmel, Paul L ^a   Kusek, John ^a   Levin, Adeera ^a   Minaker, Kenneth L ^a   Nelson, Robert ^a   Rennke, Helmut ^a   Steffes, Michael ^a   Witten, Beth ^a   Hogg, Ronald J ^a   Furth, Susan ^a   Lemley, Kevin V ^a   Portman, Ronald J ^a   Schwartz, George ^a   Lau, Joseph ^a   Balk, Ethan ^a   Perrone, Ronald D ^a   Karim, Tauqeer ^a   Rayan, Lara ^a   Al Massry, Inas ^a   Chew, Priscilla ^a   Astor, Brad C ^a   De Vine, Deirdre ^a   Eknoyan, Garabed ^a   Levin, Nathan ^a   Burrows Hudson, Sally ^a   Keane, William ^a   Kliger, Alan ^a   Latos, Derrick ^a   Mapes, Donna ^a   Oberley, Edith ^a   Willis, Kerry ^a   Bailie, George ^a   Becker, Gavin ^a   Burrowes, Jerrilynn ^a   Churchill, David ^a   Collins, Allan ^a   Couser, William ^a   DeZeeuw, Dick ^a   Garber, Alan ^a   Golper, Thomas ^a   Gotch, Frank ^a   Gotto, Antonio ^a   Greer, Joel W ^a   Grimm Jr , Richard ^a   Hannah, Ramon G ^a   Acosta, Jaime Herrera ^a   Hogg, Ronald ^a   Hunsicker, Lawrence ^a   Klag, Michael ^a   Klahr, Saulo ^a   Lewis, Caya ^a   Lowrie, Edmund ^a   Matas, Arthur ^a   McCulloch, Sally ^a   Michael, Maureen ^a   Nally, Joseph V ^a   Newmann, John M ^a   Nissenson, Allen ^a   Norris, Keith ^a   Owen Jr , William ^a   Patel, Thakor G ^a   Payne, Glenda ^a   Rivera Mizzoni, Rosa A ^a   Smith, David ^a   Star, Robert ^a   Steinman, Theodore ^a   Valderrabano, Fernando ^a   Walls, John ^a   Wauters, Jean Pierre ^a   Wenger, Nanette ^a   Briggs, Josephine ^a   more..

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; BONE DISEASE; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LABORATORY TEST; MINERAL METABOLISM; NEUROPATHY; PRACTICE GUIDELINE; PROTEINURIA; PUBLIC HEALTH; REVIEW; STAGING;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; CHILD; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; UNITED STATES;

EID: 0036176161     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (664)

1. Serum creatinine levels in the US population: Third national health and nutrition examination survey
2. Cardiovascular disease and chronic renal disease: A new paradigm
3. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third national health and nutrition examination survey (1988-1994)
4. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
5. Evaluation and management of proteinuria and nephrotic syndrome in children: Recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on Proteinuria, Risk, Assessment, Detection, Elimination (PARADE)
6. Clinical practice recommendations 2001
7. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
8. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines
9. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States
10. The prognostic significance of proteinuria: The Framingham study
11. Risk of developing end-stage renal disease in a cohort of mass screening
12. Studying the causes of kidney disease in humans: A review of methodologic obstacles and possible solutions
13. Optimization of pre-ESRD care: The key to improved dialysis outcomes
14. NKF-K/DOQI clinical practice guidelines for peritoneal dialysis adequacy: Update 2000
15. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
16. A simplified equation to predict glomerular filtration rate from serum creatinine
17. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio
18. Albumin excretion as a measure of glomerular dysfunction in children
19. Urinary albumin excretion on school children
20. Urinary albumin excretion rate and puberty in non-diabetic children and adolescents
21. First morning urinary albumin concentration is a good predictor of 24-hour urinary albumin excretion in children with type 1 (insulin-dependent) diabetes
22. Microalbuminuria in diabetic children and adolescents. Relationship with puberty and growth hormone
23. Albumin excretion in children and adolescents with insulin-dependent diabetes
24. New approach to evaluation of proteinuric states
25. Prevalence of microalbuminuria in children with type 1 (insulin-dependent) diabetes mellitus
26. Microvascular permeability to albumin and glomerular filtration rate in diabetic and normal children
27. A nationwide cross-sectional study of urinary albumin excretion rate, arterial blood pressure and blood glucose control in Danish children with type 1 diabetes mellitus
28. The prevalence of microalbuminuria in diabetic children and adolescents and its relation to puberty
29. Urinary albumin excretion in the healthy population
30. Urinary excretion of albumin in adolescents with type 1 diabetes: Persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control
31. Exercise-induced proteinuria in children and adolescents with type 1 (insulin dependent) diabetes
32. Early diagnosis of subclinical complications in insulin dependent diabetic children and adolescents
33. Glomerular function and microalbuminuria in children with insulin-dependent diabetes
34. Intermittent microalbuminuria in children with type 1 diabetes mellitus without clinical evidence of nephropathy
35. Simplified quantification of urinary protein excretion in children
36. Reversible tubular proteinuria precedes microalbuminuria and correlates with the metabolic status of diabetic children
37. Characterization of proteinuria using random urine samples
38. Age-related reference limits for urine levels of albumin, orosomucoid, immunoglobulin G and protein HC in children
39. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study
40. Variability of urine albumin excretion in normal and diabetic children
41. Freezing method affects the concentration and variability of urine proteins and the interpretation of data on microalbuminuria
42. Urine microalbumin/creatinine ratios in Singapore children
43. Urine albumin to creatinine ratio-response to exercise in diabetes
44. Different urinary albumin responses to submaximal exercise by normoalbuminuric diabetic children and controls
45. Urinary screening of elementary and junior high-school children over a 13-year period in Tokyo
46. The prevalence of heavy proteinuria and progression risk factors in children undergoing urinary screening
47. Isolated proteinuria: Analysis of a school-age population
48. Epidemiology of proteinuria. A study of 4,807 schoolchildren
49. Proteinuria. A six-year study of normal infants, preschool, and school-age populations previously screened for urinary tract disease
50. A survey of bacteriuria, proteinuria and glycosuria in five-year-old schoolchildren in canberra
51. The incidence, causes and intermittency of proteinuria in young men
52. Urinary tract infection in school children: An epidemiologic clinical and laboratory study
53. Prevalence of symptomless urinary tract disease in Birmingham schoolchildren. I. Pyuria and bacteriuria
54. Routine admission urinalysis examination in pediatric patients: A poor value
55. Frequency and significance of albumin in the urines of normal children
56. Proteinuria and hematuria in schoolchildren: Epidemiology and early natural history
57. Renal tract abnormalities detected in Australian preschool children
58. City-wide screening for urinary abnormalities in schoolboys
59. City-wide screening for urinary abnormalities in schoolgirls
60. Adolescent albuminuria: Incidence, significance, and after-history
61. Urinary albumin excretion in children: Factors related to elevated excretion in the United States population
62. Screening school children for albuminuria, proteinuria and occult blood with dipsticks
63. The multidimensional nature of renal disease: Rates and associations of albuminuria in an Australian Aboriginal community
64. Urinary biomarkers to detect significant effects of environmental and occupational exposure to nephrotoxins. IV. Current information on interpreting the health implications of tests
65. Comparative physiology of the kidney
66. Evaluation of renal function during childhood
67. Expressing glomerular filtration rate in children
68. Maturation of glomerular filtratior in preterm and mature babies
69. A simple estimate of glomerular filtration rate in full-term infants during the first year of life
70. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males
71. PAH in adult males
72. NKF-K/DOQI clinical practice guidelines for nutrition in chronic renal failure
73. Comprehensive assessment of the level of renal function at the initiation of dialysis in the MDRD study
74. Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population
75. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center
76. Late referral to maintenance dialysis: Detrimental consequences
77. Time of diagnosis of chronic renal failure and assessment of quality of life in haemodialysis patients
78. Significance of serum creatinine values in new end-stage renal disease patients
79. Initiation of dialysis is not delayed in whites with progressive renal failure
80. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist
81. Compliance with chronic disease
82. Correlates of noncompliance among renal transplant recipients
83. A study of treatment compliance following kidney transplantation
84. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence
85. Fluid noncompliance and symptomatology in end-stage renal disease: Cognitive and emotional variables
86. Factors associated with noncompliance of patients taking antihypertensive medications
87. Factors associated with medication noncompliance in rural elderly hypertensive patients
88. Family support, physical impairment, and adherence in hemodialysis: An investigation of main and buffering effects
89. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs
90. Physicians' perspectives on communicating prescription drug information
91. Changes in antihypertensive therapy: The role of adverse effects and compliance
92. Adherent and nonadherent medication-taking in elderly antihypertensive patients
93. The patient's view of hypertension and compliance
94. Compliance with antihypertensive therapy among elderly Medicaid enrollees: The roles of age, gender, and race
95. "Non-compliance": Meaningful construct or destructive, sticky, stigmatizing label?
96. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. September 14-15, 1995
97. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The Third National Health and Nutrition Examination Survey, 1988-1994
98. Prevalence of hypertension in the US adult population
99. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
100. Excerpts from the 2000 US renal data system annual data report: Atlas of end stage renal disease in the United States
101. Nonnarcotic analgesics: Prevalence and estimated economic impact of toxicities
102. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal
103. Longitudinal studies on the rate of decline in renal function with age
104. Serum creatinine as an index of renal function: New insights into old concepts
105. Utility of radioscopic filtration markers in chronic renal insufficiency: Simultaneous comparison of 125I-iothalamate, 169Yb-DPTA, and inulin. The modification of diet in renal diseases study
106. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis
107. Cystatin for estimation of glomerular filtration rate?
108. Limitations of creatinine as a filtration marker in glomerulopathic patients
109. Serum creatinine and renal function
110. Assessing the effectiveness of therapy to prevent progression of renal disease
111. Predicting glomerular function from adjusted serum creatinine
112. Prediction of creatinine clearance from serum creatinine
113. Estimation of creatinine clearance when urine cannot be collected
114. A simple estimate of glomerular filtration rate in adolescent boys
115. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
116. Estimation of glomerular filtration rate in anorectic adolescents
117. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: Noninvasive assessment of body composition and growth
118. Estimation of glomerular filtration rate from plasma creatinine concentration in children
119. Assessment of renal function
120. Evaluation of a height/plasma creatinine formula in the measurement of glomerular filtration rate
121. Letter: Creatinine clearance: Bedside estimate
122. Computer-assisted prescribing of kanamycin for patients with renal insufficiency
123. Influence of range of renal function and liver disease on predictability of creatinine clearance
124. Creatinine clearance estimation from serum creatinine values: An analysis of three mathematical models of glomerular function
125. Nomogram for estimating creatinine clearance
126. Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: Results from the African-American Study of Kidney disease and hypertension (AASK) pilot study
127. A comparative analysis of formulas used to predict creatinine clearance
128. Comparison of creatinine clearance estimation methods in patients with trauma
129. Plasma creatinine level and creatinine clearance as a test of renal function
130. Prediction of creatinine clearance from serum creatinine concentration based on lean body mass
131. Prediction of GFR from serum creatinine
132. Erythrocytes after renal transplantation: Risk factors and relationship with GFR
133. Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate
134. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study
135. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass
136. Serum albumin for estimating creatinine clearance in the elderly with muscle atrophy
137. Rapid evaluation of creatinine clearance
138. An individual nomogram for determination of glomerular filtration rate from plasma creatinine
139. Predictive performance of equations to estimate creatinine clearance from serum creatinine in Japanese patients with congestive heart failure
140. A useful method for predicting creatinine clearance in children
141. Comparison of methods of estimating creatinine clearance in children
142. Urinary excretion of calcium and magnesium in children
143. Limitations concerning the use in children of the relationship between plasma creatinine and body height to derive glomerular filtration rate
144. Estimation of creatinine clearance in children: Comparison of six methods
145. A computer program for estimation of creatinine clearance from unstable serum creatinine levels, age, sex, and weight
146. Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction
147. Which routine test for kidney function?
148. Estimating creatinine clearance in children: Comparison of three methods
149. Assessment of glomerular filtration rate in preterm infants by serum creatinine: Comparison with inulin clearance
150. Inaccuracy of estimated creatinine clearance for prediction of iothalamate glomerular filtration rate
151. Use of the serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy
152. Quick prediction of creatinine clearance without the necessity of urine collection
153. African-American study of hypertension and kidney disease. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate
154. The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate
155. Predicted creatinine clearance to assess glomerular filtration rate in chronic renal disease in humans
156. Estimating GFR from creatinine clearance in renal transplant recipients
157. Predictive performance of renal function estimate equations in renal allografts
158. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate
159. Limitations to body length/serum creatinine ratio as an estimate of glomerular filtration in children
160. Creatinine clearance following cimetidine for estimation of glomerular filtration rate
161. Assessment of glomerular filtration rate in children
162. Glomerular filtration rate in children following renal transplantation
163. Serum creatinine level and renal function in children
164. Serum creatinine, height, and weight do not predict glomerular filtration rate in children with IDDM
165. Cystatin C - A new marker of glomerular filtration rate in children independent of age and height
166. Influence of urography on renal function in children. A double blind study with metrizoate and iohexol
167. The clearance of iohexol as a measure of the glomerular filtration rate in children with chronic renal failure
168. A single plasma sample method for estimation of the glomerular filtration rate in infants and children using iohexol. II: Establishment of the optimal plasma sampling time and a comparison with the 99Tcm-DTPA method
169. A single plasma sample method for estimation of the glomerular filtration rate in infants and children using iohexol. I: Establishment of a body weight-related formula for the distribution volume of iohexol
170. Glomerular filtration rate estimated by X-ray fluorescence technique in children: Comparison between the plasma disappearance of 99Tcm-DTPA and iohexol after urography
171. Assessing renal function from creatinine measurements in adults with chronic renal failure
172. Effect of chronic salt and water loading on the tubular defects of a child with Fanconi syndrome (cystinosis)
173. Serum cystatin C as an endogenous marker of the renal function - A review
174. Serial measurements of GFR in infants using the continuous iothalamate infusion technique
175. Creatinine for estimation of glomerular filtration rate
176. Comparison of plasma disappearance and standard clearance techniques for measuring glomerular filtration rate in children with and without vesico-ureteric reflux
177. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents
178. The accuracy of laboratory measurements in clinical chemistry: A study of 11 routine chemistry analytes in the College of American Pathologists Chemistry Survey with fresh frozen serum, definitive methods, and reference methods
179. A new simple and rapid method to monitor the renal function based on pharmacokinetic consideration of endogenous creatinine
180. Lack of evidence that formula-derived creatinine clearance approximates glomerular filtration rate in pediatric intensive care population
181. Predictive ability of creatinine clearance estimate models in pediatric bone marrow transplant patients
182. Length/serum creatinine ratio does not predict measured creatinine clearance in critically ill children
183. Inaccuracy of the Schwartz formula in estimating glomerular filtration rate in Nigerian children
184. Capillary electrophoresis for the determination of glomerular filtration rate using nonradioactive iohexol
185. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy
186. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy
187. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy
188. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis
189. Evaluation of a rapid screening test for microalbuminuria with a spot measurement of urine albumin-creatinine ratio
190. A screening test for microalbuminuria in type 1 (insulin-dependent) diabetes
191. The use of the Micral-Test strip to identify the presence of microalbuminuria in people with insulin dependent diabetes mellitus (IDDM) participating in the EUCLID study
192. Evaluation of a dipstick test for microalbuminuria in three different clinical settings, including the correlation with urinary albumin excretion rate
193. Assessment of a new dipstick test in screening for microalbuminuria in patients with hypertension
194. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples
195. Use of single voided urine samples to estimate quantitative proteinuria
196. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy
197. Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample
198. Assessment of proteinuria by using the protein/creatinine ratio of single-voided urine
199. Quantitation of proteinuria in kidney transplant patients: Accuracy of the urinary protein/creatinine ratio
200. Single-void urine samples can be used to estimate quantitative microalbuminuria
201. Glomerular filtration rate and urinary albumin excretion rate in systemic lupus erythematosus
202. Evaluation of variability of proteinuria indices
203. Quantitation of proteinuria using protein-creatinine ratio in random urine samples
204. Quantitation of proteinuria by use of single random spot urine collection
205. Use of single voided urine samples to estimate quantitative proteinuria in children
206. Assessment of proteinuria using random urine samples
207. Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children
208. Screening tests to detect microalbuminuria in children with diabetes
209. Chronic renal insufficiency in children and adolescents: The 1996 annual report of NAPRTCS
210. Lessons learned from the Japanese nephritis screening study
211. Recommendations for preventive pediatric health care
212. Screening dipstick analysis: A time to change
213. Diabetic nephropathy
214. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
215. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
216. When should ACE inhibitors be given to normotensive patients with IDDM?
217. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple risk factor intervention trial
218. Progression of borderline increases in albuminuria in adolescents with insulin-dependent diabetes mellitus
219. Laboratory assessment of renal disease: Clearance, urinalysis and renal biopsy
220. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases
221. Differential excretion of urinary proteins in children with vesicoureteric reflux and reflux nephropathy
222. Prospective evaluation of urinary N-acetyl-beta-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients
223. Predictive value of tubular markers for the development of microalbuminuria in adolescents with diabetes
224. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy
225. Characterization of proteinuria in primary glomerulonephritides. SDS-PAGE patterns: Clinical significance and prognostic value of low molecular weight ("tubular") proteins
226. Pattern of proteinuria in IgA nephritis by SDS-PAGE: Clinical significance
227. Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy
228. Immunohistochemical and urinary markers of podocyte injury
229. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis
230. + cells in urine using flow cytometry: A useful tool for monitoring disease activity of IgA nephropathy
231. Urinary podocytes for the assessment of disease activity in lupus nephritis
232. Urinary excretion of podocytes in patients with diabetic nephropathy
233. Epidemiology of cardiovascular disease in the United States
234. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960-1991
235. Prevention of cardiovascular disease in hypertensive patients with normal renal function
236. Hypertension in chronic renal disease
237. Preserving renal function in adults with hypertension and diabetes: A consensus approach
238. Report from the 1995 core indicators for peritoneal dialysis study group
239. 1995 Update of the working group reports on chronic renal failure and renovascular hypertension
240. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
241. Blood pressure control, proteinuria and the progression of renal disease: The modification of diet in renal disease study
242. The collaborative transplant study. Association of chronic kidney graft failure with recipient blood pressure
243. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
244. Achievement and safety of a low blood pressure goal in chronic renal disease
245. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study
246. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
247. Clinical epidemiology of cardiovascular disease in chronic renal disease
248. "U" curve association of blood pressure and mortality in hemodialysis patients
249. Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort
250. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
251. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000
252. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency
253. Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function
254. Characterization of the anemia associated with chronic renal insufficiency
255. Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved
256. Radioimmunoassay of erythropoietin in chronic uraemia of anephric patients
257. European best practice guidelines for the management of anaemia in patients with chronic renal failure
258. The rate and control of baseline red cell production in hema-tologically stable uremic patients
259. Mechanism of the anemia of chronic renal failure
260. Defining a renal anemia management period
261. Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients
262. Erythropoiesis in patients with renal failure undergoing chronic dialysis
263. Trends in anemia treatment with erythropoietin usage and patient outcomes
264. Outcome and risk factors for left ventricular disorders in chronic uraemia
265. Cardiovascular disease in chronic renal insufficiency
266. Anemia management in patients with chronic renal insufficiency
267. The impact of hematocrit levels and Erythropoietin treatment on overall and cardiovascular mortality and morbidity: The experience of Lombardy Registry
268. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
269. Double-blind, placebo controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients
270. Effectiveness and safety of recombinant human erythropoietin in predialysis patients
271. Recombinant human erythropoietin: 10 Years of clinical experience
272. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
273. Erythrocyte ferritin levels in chronic renal failure patients
274. Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity
275. Diabetes mellitus increases the severity of anemia in nondialyzed patients with renal failure
276. Serum erythropoietin (ESF) titers in anemia of chronic renal failure
277. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states
278. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis
279. Effect of long-term low-dose aluminum-containing agents on hemoglobin synthesis in patients with chronic renal insufficiency
280. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients
281. Cardiovascular effects of recombinant human erythropoietin in predialysis patients
282. Study of the effect of recombinant erythropoietin on renal anaemia in predialysis patients with chronic renal failure
283. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease
284. Analysis of the quantitative relationship between anemia and chronic renal failure
285. Effect of recombinant human erythropoietin on renal function in humans
286. Effect of cyclosporine and delayed graft function on posttransplantation erythropoiesis
287. Effect of correction of anemia on the glomerular filtration rate in chronic renal failure
288. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients
289. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients
290. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure
291. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin
292. Erythropoietin deficiency in hyporeninemia
293. Red cell life span in nephritis and in hepatic nephrosis
294. Dynamics of erythropoiesis following renal transplantation
295. Iron status as measured by serum ferritin: The marker and its limitations
296. Erythropoietin and iron
297. Erythropoietin in polycystic kidney
298. Nutrition in end-stage renal disease
299. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease
300. Correction of acidosis in hemodialysis decreases whole-body protein degradation
301. Cost-effectiveness of medical nutrition therapy
302. Nutrition and mortality in hemodialysis
303. The relative contribution of measured variables to death risk among hemodialysis patients
304. Initiation of dialysis
305. Predictors of hospitalization and death amongst pre-dialysis patients: A retrospective study
306. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study
307. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
308. Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD study
309. Spontaneous dietary protein intake during progression of chronic renal failure
310. Nutritional considerations in the treatment of patients with chronic uremia
311. Factors causing malnutrition in patients with chronic uremia
312. Influence of acidosis on protein metabolism
313. Derangements of the somatotropic hormone axis in chronic renal failure
314. Chronic renal failure: An overview from a pediatric perspective
315. Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure
316. C reactive protein in patients with chronic renal diseases
317. Inflammation and acidosis are important independent predictors of hypoalbuminuria in renal insufficiency
318. Role of the systemic inflammatory response syndrome in the development of protein-calorie malnutrition in ESRD
319. The systemic inflammatory response and its impact on iron nutriture in end-stage renal disease
320. Malnutrition, cardiac disease, and mortality: An integrated point of view
321. Long-term adaptive responses to dietary protein restriction in chronic renal failure
322. Nutritional status of patients with different levels of chronic renal insufficiency
323. Serum lipid changes associated with modified protein diets: Results from the feasibility phase of the modification of diet in renal disease study
324. Protein intake and the nutritional status in patients with pre-dialysis chronic renal failure on unrestricted diet
325. Protein intake in renal disease
326. Should protein intake be restricted in predialysis patients?
327. Outcome of nutritional status and body composition of uremic patients on a very low protein diet
328. Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia
329. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet
330. A crossover comparison of progression of chronic renal failure: Ketoacids versus amino acids
331. Risk factors of renal failure progression two years prior to dialysis
332. Energy expenditure in patients with chronic renal failure
333. Effect of low protein diet and surplus of essential amino acids on the serum concentration and the urinary excretion of methylguanidine and guanidinosuccinic acid in chronic renal failure
334. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure
335. Can renal replacement be deferred by a supplemented very low protein diet?
336. Nutritional state of severe chronic renal failure patients on a low-protein supplemented diet
337. Effect of dietary protein restriction on proteinuria in noninsulin-dependent diabetic patients with nephropathy
338. Nutritional assessment in patients with early renal insufficiency on long-term low protein diet
339. Comparative outcome of patients on a conventional low protein diet versus a supplemented diet in chronic renal failure
340. Evaluation of nutritional status in the GDR trial
341. Nutritional treatment of renal failure in type 1 diabetic nephropathy
342. The metabolic consequences of the correction of acidosis in uraemia
343. Angiotensin-converting enzyme insertion/deletion polymorphism and diabetic albuminuria in patients with NIDDM followed up for 9 years
344. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus
345. Dietary control may influence several risk factors in patients with chronic renal failure
346. Metabolic consequences of feeding a high-carbohydrate, high-fiber diet to diabetic patients with chronic kidney failure
347. Adaptation to low-protein diets in renal failure: Leucine turnover and nitrogen balance
348. Measurement of body composition in chronic renal failure: Comparison of skinfold anthropometry and bioelectrical impedance with dual energy X-ray absorptiometry
349. Nutritional state in patients on long-term low-protein diet or with nephrotic syndrome
350. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet
351. The effect of a keto acid-amino acid supplement to a restricted diet on the progression of chronic renal failure
352. Factors associated with adherence to the dietary protein intervention in the modification of diet in renal disease study
353. Nutrition intervention program of the modification of diet in renal disease study: A self-management approach
354. Dietary satisfaction correlated with adherence in the Modification of Diet in Renal Disease Study
355. Registered dietitian time requirements in the Modification of Diet in Renal Disease Study
356. The spectrum of bone disease in end-stage renal failure - An evolving disorder
357. The contribution of acidosis to renal osteodystrophy
358. Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: Effect of calcitriol treatment
359. Are we mismanaging calcium and phosphate metabolism in renal failure?
360. Control of renal bone disease
361. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease
362. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure
363. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency
364. Calciphylaxis in chronic renal failure
365. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients
366. Aluminum-associated bone disease in chronic renal failure: High prevalence in a long-term dialysis population
367. Diagnosis of renal osteodystrophy: When and how to use biochemical markers and non-invasive methods: When bone biopsy is needed
368. The role of bone biopsy in clinical practice and research
369. Pathogenesis of secondary hyperparathyroidism
370. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity
371. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis
372. Some biochemical, histological, radiological and clinical features of renal osteodystrophy
373. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH
374. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro
375. Altered divalent ion metabolism in early renal failure: Role of 1,25(OH)2D
376. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure
377. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease
378. Hyperphosphatemia in end-stage renal disease patients: Pathophysiological consequences
379. Primary hyperparathyroidism and the risk of fracture: A population-based study
380. Secondary hyperparathyroidism in patients from Western Australia with hip fracture: Relationship to type of hip fracture, renal function, and vitamin D deficiency
381. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism
382. Risk factors for vertebral fractures in renal osteodystrophy
383. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone
384. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
385. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
386. Phosphate excess and progressive renal failure: The precipitation-calcification hypothesis
387. Predictors of survival in continuous ambulatory peritoneal dialysis patients: A five-year prospective study
388. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department
389. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure
390. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure
391. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure
392. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism
393. Immunoreactive parathyroid hormone in early and advanced renal failure
394. Determinants of serum 1,25(OH)2D levels in renal disease
395. Intact parathyroid hormone levels in renal insufficiency
396. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure
397. Levels of serum 1,25(OH)2D in patients with pre-dialysis chronic renal failure
398. Parathyroid function after renal transplantation: Interrelationships between renal function, serum calcium and serum parathyroid hormone in normocalcemic long-term survivors
399. Bone histology in incipient and advanced renal failure
400. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure
401. Calcium and vitamin D homeostasis in patients with heavy proteinuria
402. The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function
403. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure
404. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH) 2D3 treatment
405. Bone composition and parathyroid function in chronic renal failure
406. Renal handling of phosphate in relation to serum parathyroid hormone levels
407. Early skeletal changes of the hand phalanges in patients with chronic renal failure
408. Effect of parathyroid hormone on bone resorption in uremic patients
409. Hyperparathyroidism and renal failure
410. Experience with a radioimmunoassay of parathyroid hormone in human sera
411. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects
412. Control of phosphate excretion in uremic man
413. Study of intestinal absorption of calcium in patients with renal failure
414. The physicochemical state and renal handling of divalent ions in chronic renal failure
415. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure
416. Calcium metabolism in patients with chronic non-dialytic renal disease
417. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease
418. Renal osteodystrophy in early chronic renal failure
419. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study
420. Degree and course of skeletal demineralization in patients with chronic renal insufficiency
421. Neurology and the kidney
422. Nervous system manifestations of renal failure
423. Uremic polyneuropathy: A clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients
424. Polysomnographic sleep measures in patients with uremic and idiopathic restless legs syndrome
425. Autonomic function in type I diabetes mellitus complicated by nephropathy. A cross-sectional analysis in the presymptomatic phase
426. Mechanisms of autonomic nervous system dysfunction in uremia
427. Relationships among glomerular filtration rate, albuminuria, and autonomic nerve function in insulin-dependent and non-insulin-dependent diabetes mellitus
428. New electrophysiological assessments for the early diagnosis of encephalopathy and peripheral neuropathy in chronic uraemia
429. The influence of glomerular filtration rate on uremic polyneuropathy
430. Observations on peripheral neuropathy in chronic uraemics
431. The peripheral nerve function in chronic renal failure. VI. The relationship between sensory and motor nerve conduction and kidney function, azotemia, age, sex, and clinical neuropathy
432. Detection of uremic neuropathy by reflex response latency
433. Quantitative indices of clinical uremia
434. Nerve conduction times in uremia
435. Assessing end-stage renal disease patients' functioning and well-being: Measurement approaches and implications for clinical practice
436. The medical outcomes study. An application of methods for monitoring the results of medical care
437. Assessing health and quality of life outcomes in dialysis: A report on an Institute of Medicine workshop
438. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance
439. Physical functioning and exercise capacity in patients on dialysis
440. Rehabilitation, aging and chronic renal disease
441. Dismal rehabilitation in geriatric inner-city hemodialysis patients
442. Clinical correlates of functional status in patients with chronic renal insufficiency
443. Hypertension and health-related quality of life. An epidemiological study in Sweden
444. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture
445. Quality of life in long-term home enteral nutrition patients
446. Responsiveness of the SF-36 among veterans with diabetes mellitus
447. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients
448. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
449. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
450. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin
451. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia
452. Cross-sectional study of quality of life and symptoms in chronic renal disease patients: The modification of diet in renal disease study
453. Quality of life in predialysis end-stage renal disease patients at the initiation of dialysis therapy
454. Quality of life and psychosocial relationships in patients with chronic renal insufficiency
455. Quality of life in predialytic uremic patients
456. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey
457. Odour perception in chronic renal disease
458. Perception of illness and depression in chronic renal disease
459. Work disability, functional limitations, and the health status of kidney transplantation recipients posttransplant
460. Measurement of quality of life in end-stage renal disease: The time trade-off approach
461. The association between chronic diseases and depressive symptomatology in older Mexican Americans
462. Formal literature review of quality of life instruments used in end stage renal disease
463. Predictors of the progression of renal disease in the modification of diet in renal disease study
464. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis
465. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation
466. Nephrology forum: Measurement of renal function in chronic renal disease
467. Progression of chronic renal failure in man
468. A simple method of estimating progression of chronic renal failure
469. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance
470. Slope of serial glomerular filtration rate and the progression of diabetic glomerular disease
471. The quantitative relationship between treated blood pressure and progression of diabetic renal disease
472. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy
473. Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure
474. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus
475. Effects of dietary protein restriction on the progression of moderate renal disease in the MDRD study
476. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: A 10-year follow-up study
477. The changing course of diabetic nephropathy: Low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria
478. Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease
479. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension
480. The clinical course of renal function in NIDDM patients with normo- and microalbuminuria
481. Dyslipidaemia and the progression of renal disease in chronic renal failure patients
482. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism
483. Factors affecting progression in advanced chronic renal failure
484. Spontaneous changes in the rate of decline in reciprocal serum creatinine: Errors in predicting the progression of renal disease from extrapolation of the slope
485. Dietary protein restriction and the progression of chronic renal disease: What have all the results of the MDRD study shown?
486. Nephrology forum: Dietary protein restriction in patients with chronic renal failure
487. High mortality and poor quality of life during predialysis period in type II diabetic patients with diabetic nephropathy
488. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
489. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans
490. Progression of diabetic nephropathy
491. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program
492. Hypertension-related renal injury: A major contributor to end-stage renal disease
493. A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: The atherosclerosis risk in communities study
494. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy
495. The 10-year incidence of renal insufficiency in people with type 1 diabetes
496. Plasma levels of lipoprotein (a) do not reflect progression of human chronic renal failure
497. Reversed circadian blood pressure rhythm independently predicts endstage renal failure in non-insulin-dependent diabetes mellitus subjects
498. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency
499. The nephrology of non-insulin-dependent diabetes: Predictors of outcome relative to diverse patterns of renal injury
500. Membranous nephropathy: Predictors of terminal renal failure
501. Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis
502. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine
503. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia
504. Protein-restricted diets in chronic renal failure: A four year follow-up shows limited indications
505. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency
506. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients
507. Standards of medical care for patients with diabetes mellitus, position statement. Clinical practice recommendations 2001
508. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
509. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria
510. UK prospective diabetes study 33: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
511. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: A randomized prospective 6-year study
512. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The steno type 2 randomised study
513. Update on the 1987 Task Force report on high blood pressure in children and adolescents: A working group report from the National High Blood Pressure Education Program
514. Morbidity and mortality in patients randomised to double-blind treatment wit a long-acting calcium-channel blocker or diuretic the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
515. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morobidity in the Swedish trial in old patients with hypertension-2 study
516. Diabetic hypertensive patients. Is this a group in need of particular care and attention?
517. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes
518. Effects of intensive blood pressure lowering a low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial
519. Angiotensin-converting enzyme inhibitor therapy for nondiabetic progressive renal disease
520. Antihypertensive drugs, dietary salt, and renal protection: How low should you go with which therapy?
521. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
522. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
523. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
524. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
525. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
526. Angiotensin-converting enzyme inhibitors and the progression of non-diabetic renal disease: A meta-analysis of patient level data
527. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
528. Effect of a ketoacid-aminoacid-supplemented very low protein diet on the progression of advanced renal disease: A reanalysis of the MDRD feasibility study
529. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis
530. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function
531. Hypercholesterolemia - A determinant of renal function loss and deaths in IDDM patients with nephropathy
532. Effects of hypertension and dyslipidemia on the decline in renal function
533. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study
534. Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study
535. Associated effect of hepatic hydroxymethylglutaryl coenzyme A reductase + angiotensin converting enzyme inhibitors on the progression of renal failure in hypertensive subjects
536. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy
537. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
538. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria
539. Effect of pravastatin on hypercholesterolemia associated with proteinuria
540. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy
541. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone
542. Can reduction in hypertriglyceridemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
543. Reduction of albumin excretion rate in normotensive microalbumiuric type 2 diabetic patients during long-term simvastatin treatment
544. Simvastatin in nephrotic syndrome
545. Angiotensin converting enzyme inhibitor and probucol suppress time-dependent increase in urinary type IV collagen excretion of NIDDM with early nephropathy
546. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy
547. The effect of lipid reduction on renal disease progression: A meta-analysis
548. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: Results of a multicenter study
549. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
550. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin
551. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period
552. Acute renal failure
553. The differential diagnosis of acute renal failure
554. Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies
555. Microalbuminuria: Implications for micro and macrovascular disease
556. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy
557. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
558. Microalbuminuria predicts mortality in non-insulin-dependent diabetes
559. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors
560. Albuminuria in non-insulin-dependent diabetes mellitus. Prevalence, causes, and consequences
561. Microalbuminuria: Implications for micro and macrovascular disease
562. Microalbuminuria in non-insulin-dependent diabetes
563. Microalbuminuria: Prognostic and therapeutic implications in diabetes mellitus
564. Microalbuminuria in patients with NIDDM: An overview
565. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature
566. Diabetic nephropathy. Future avenue
567. Cardiovascular disease in insulin-dependent diabetes mellitus: Similar rates but different risk factors in the US compared with Europe
568. Surrogate endpoints and renal protection: Focus on microalbuminuria
569. Clinical usefulness of measurement of urinary albumin excretion in diabetes mellitus
570. Microalbuminuria: Pathogenesis, prognosis and management
571. Relationships among diabetes, microalbuminuria, and ACE inhibition
572. Microalbuminuria: A marker to increased renal and cardiovascular risk in diabetes mellitus
573. Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas
574. Preserving the diabetic kidney
575. Microalbuminuria: An important diagnostic tool
576. Proteinuria and mortality in diabetes: The WHO multinational study of vascular disease in diabetes
577. Prevalence and associated features of albuminuria in Koreans with NIDDM
578. Prevalence of diabetic nephropathy in non-insulin dependent diabetics
579. Coronary heart disease prevalence and its relation to risk factors in American Indians
580. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of noninsulin-dependent diabetes
581. Relationship between retinal and glomerular lesions in IDDM patients
582. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients
583. Proliferative diabetic retinopathy: At risk patients identified by early detection of microalbuminuria
584. Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM
585. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
586. Management of dyslipidemia in adults with diabetes
587. Aspirin therapy in diabetes
588. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes
589. Diabetes and cardiovascular disease. A statement for health-care professionals from the American Heart Association
590. Diabetic retinopathy
591. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy
592. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus
593. Effect of proteinuria on mortality in NIDDM
594. Nephropathy in patients with type 2 diabetes mellitus
595. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
596. The clinical epidemiology of cardiac disease in chronic renal failure
597. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency
598. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study
599. Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke
600. Interventions for other risk factors: Tobacco use, physical inactivity, menopause, and homocysteine
601. Hyperlipidemia in patients with chronic renal disease
602. Microalbuminuria in essential hypertension: Significance, pathophysiology, and therapeutic implications
603. Cardiovascular disease risk factors in chronic renal insufficiency
604. Proteinuria: Its clinical importance and role in progressive renal disease
605. Thrombogenic risk factors for cardiovascular disease in dialysis patients
606. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients
607. Epidemiology of cardiovascular risk factors in chronic renal disease
608. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study
609. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension
610. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program
611. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial
612. Increased serum lipoprotein(a) levels in patients with early renal failure
613. Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure
614. Risk factors for 5-year mortality in older adults: The cardiovascular health study
615. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction
616. Poor long-term survival after coronary angiography in patients with renal insufficiency
617. Microalbuminuria as predictor of increased mortality in elderly people
618. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction
619. Serum creatinine: An independent predictor of survival after stroke
620. Proteinuria as a biomarker: Risk of subsequent morbidity and mortality
621. Urinary albumin excretion - A predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middleaged nondiabetic normal and hypertensive men
622. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: A prospective study
623. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects
624. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus
625. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study
626. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington diabetes survey
627. Clinical practice guidelines and performance measures in ESRD
628. Clinical practice guidelines in end-stage renal disease: A strategy for implementation
629. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients?
630. Users' guides to the medical literature. V. How to use an article about prognosis
631. Plan and operation of the third national health and nutrition examination survey, 1988-1994
632. Sample design: Third national health and nutrition examination survey, 1988-1994
633. Laboratory assessment of renal disease: Clearance, urinalysis, and renal biopsy
634. Creatinine clearance as a measure of GFR in screenees for the African-American study of kidney disease and hypertension pilot study
635. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate
636. A solid-phase fluorescent immunoassay for the measurement of human urinary albumin
637. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus
638. Total body water volumes for adult males and females estimated from simple anthropometric measurements
639. A method for estimating nitrogen intake of patients with chronic renal failure